These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24880920)

  • 21. The US Food and Drug Administration 515 Program Initiative: Addressing the Evidence Gap for Widely Used, High-Risk Cardiovascular Devices?
    Rathi VK; Kesselheim AS; Ross JS
    JAMA Cardiol; 2016 May; 1(2):117-8. PubMed ID: 27437879
    [No Abstract]   [Full Text] [Related]  

  • 22. Medical Device Classification Procedures: Incorporating Food and Drug Administration Safety and Innovation Act Procedures. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2018 Dec; 83(241):64443-58. PubMed ID: 30557920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmaceuticals and medical devices: medical devices. Issue brief.
    Health Policy Tracking Service, A Service of Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-24. PubMed ID: 21374838
    [No Abstract]   [Full Text] [Related]  

  • 24. Effective date of requirement for premarket approval for three class III preamendments devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Aug; 76(158):50663-7. PubMed ID: 21845785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Role of the FDA and Regulatory Approval of New Devices for Diabetes Care.
    Jazowski SA; Winn AN
    Curr Diab Rep; 2017 Jun; 17(6):40. PubMed ID: 28439847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The "art" of medicine and the "smokescreen" of the randomized trial off-label use of vascular devices.
    Ansel GM; Jaff MR
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):998-1002. PubMed ID: 19021289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceuticals and medical devices: medical devices. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-25. PubMed ID: 20217916
    [No Abstract]   [Full Text] [Related]  

  • 28. Past, present, and future regulatory aspects of ventricular assist devices.
    Patel-Raman SM; Chen EA
    J Cardiovasc Transl Res; 2010 Dec; 3(6):600-3. PubMed ID: 21046301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA regulation of cardiovascular devices and opportunities for improvement.
    Dhruva SS; Redberg RF
    J Interv Card Electrophysiol; 2013 Mar; 36(2):99-105. PubMed ID: 23263896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 31. The law on cardiovascular devices: the role of the Food and Drug Administration and physicians in its implementation.
    Rahimtoola SH; Rahmoeller GA
    Circulation; 1980 Nov; 62(5):919-24. PubMed ID: 7418175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contrasting clinical evidence for market authorisation of cardio-vascular devices in Europe and the USA: a systematic analysis of 10 devices based on Austrian pre-reimbursement assessments.
    Wild C; Erdös J; Zechmeister I
    BMC Cardiovasc Disord; 2014 Nov; 14():154. PubMed ID: 25366498
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
    Tylenda CA; Weintraub M
    Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Industry regulation and its relationship to the rapid marketing of medical devices].
    Matsuoka A
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2012; (130):13-20. PubMed ID: 23243983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Making sense of the food and drug administration.
    Connor JA
    Semin Pediatr Surg; 2006 Nov; 15(4):293-301. PubMed ID: 17055960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory aspects of invasive glucose measurements.
    Gutman S; Bernhardt P; Pinkos A; Moxey-Mims M; Knott T; Cooper J
    Diabetes Technol Ther; 2002; 4(6):775-7. PubMed ID: 12685800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Food and Drug Administration Efforts to Mitigate Contact Lens Discomfort.
    Hampton D; Green JA; Robboy M; Eydelman M
    Eye Contact Lens; 2017 Jan; 43(1):2-4. PubMed ID: 27941360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Introduction of innovative high-risk medical devices in Europe: are clinical efficacy and safety guaranteed?].
    Stordeur S; Vinck I; Neyt M; Van Brabandt H; Hulstaert F
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):105-10. PubMed ID: 23477881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolution of substantial equivalence in FDA's premarket review of medical devices.
    Goldberger BA
    Food Drug Law J; 2001; 56(3):317-37. PubMed ID: 11944642
    [No Abstract]   [Full Text] [Related]  

  • 40. Don’t Try This at Home: the FDA’s Restrictive Regulation of Home Testing Devices.
    Baird S
    Duke Law J; 2017 Nov; 67(2):383-426. PubMed ID: 29469551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.